{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:07Z","timestamp":1791302467587,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004233","name":"Universitat Polit\u00e8cnica de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.neuropharm.2012.09.003","type":"journal-article","created":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T15:08:58Z","timestamp":1347376138000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Antidepressant-like properties of three new \u03b12-adrenoceptor antagonists"],"prefix":"10.1016","volume":"65","author":[{"given":"Carolina","family":"Muguruza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Javier","family":"Meana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Urig\u00fcen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Callado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.09.003_bib1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1471-4159.1998.70031114.x","article-title":"Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims","volume":"70","author":"Callado","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1471-4159.1990.tb04599.x","article-title":"Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in\u00a0vivo by noradrenergic terminals","volume":"55","author":"Carboni","year":"1990","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A\u00a0double-blind, placebo controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","article-title":"Mirtazapine: a review of its use in major depression and other psychiatric disorders","volume":"23","author":"Croom","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00171072","article-title":"Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice","volume":"354","author":"De Angelis","year":"1996","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.mp.4000904","article-title":"Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex","volume":"6","author":"Devoto","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1471-4159.2004.02866.x","article-title":"Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex","volume":"92","author":"Devoto","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157015906776359559","article-title":"On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?","volume":"4","author":"Devoto","year":"2006","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.pnpbp.2003.11.018","article-title":"Central monoamines and their role in major depression","volume":"28","author":"Elhwuegi","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.mp.4001067","article-title":"Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors","volume":"7","author":"Gonzalez-Maeso","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0269881107065738","article-title":"Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness","volume":"21","author":"Hannan","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib14","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.pnpbp.2007.05.002","article-title":"Effect of various classes of antidepressants in behavioral paradigms of despair","volume":"31","author":"Kulkarni","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/(SICI)1099-1077(199903)14:2<75::AID-HUP68>3.0.CO;2-X","article-title":"Neuropharmacology of antidepressants that modify central noradrenergic and serotonergic function: a short review","volume":"14","author":"Leonard","year":"1999","journal-title":"Hum. Psychopharmacol. Clin."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF00177912","article-title":"The use of a plus-maze to measure anxiety in the mouse","volume":"92","author":"Lister","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejphar.2008.11.010","article-title":"Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains","volume":"602","author":"Mason","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuropharm.2012.05.020","article-title":"Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies","volume":"63","author":"Masana","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1471-4159.1998.71020790.x","article-title":"Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in\u00a0vivo modulation of cortical noradrenaline release by the antidepressant desipramine","volume":"71","author":"Mateo","year":"1998","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2009.12.001","article-title":"Accelerating response to antidepressant treatment in depression: a review and clinical suggestions","volume":"34","author":"Nakajima","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.euroneuro.2010.07.008","article-title":"In\u00a0vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by alpha2-adrenoceptor antagonism","volume":"20","author":"Ortega","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib23","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","article-title":"Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study","volume":"65","author":"Pallanti","year":"2004","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib24","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1471-4159.1994.63010195.x","article-title":"Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats","volume":"63","author":"Pozzi","year":"1994","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v62n0509","article-title":"Does mirtazapine have a more rapid onset than SSRI's?","volume":"62","author":"Quitkin","year":"2001","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0893-133X(00)00214-1","article-title":"Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA\/5-HT reuptake Inhibition in the rat forced swimming test","volume":"24","author":"R\u00e9n\u00e9ric","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-4328(02)00203-6","article-title":"In the rat forced swimming test, chronic but not subacute administration of dual 5-HT\/NA antidepressant treatments may produce greater effects than selective drugs","volume":"136","author":"R\u00e9n\u00e9ric","year":"2002","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib30","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1021\/jm800026x","article-title":"Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants","volume":"51","author":"Rodriguez","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/jm800838r","article-title":"Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor ligands: searching for structure-activity relationships","volume":"52","author":"Rodriguez","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.npp.1300418","article-title":"Addition of the alpha 2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response","volume":"29","author":"Sanacora","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.biopsych.2010.07.023","article-title":"\u03b12-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims","volume":"68","author":"Valdiz\u00e1n","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.09.003_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00008877-200302000-00009","article-title":"The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test","volume":"14","author":"Varty","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib36","first-page":"CD006528","article-title":"Mirtazapine versus other antidepressive agents for depression","volume":"12","author":"Watanabe","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2012.09.003_bib37","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1523\/JNEUROSCI.2309-09.2010","article-title":"Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment","volume":"30","author":"Yanpallewar","year":"2010","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812004753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812004753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:42:02Z","timestamp":1758436922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812004753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":37,"alternative-id":["S0028390812004753"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.09.003","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant-like properties of three new \u03b12-adrenoceptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}